Brief: Citius Pharma Enrolls First Patient In Study Of Halo-Lido For Prescription Treatment Of Hemorrhoids
26/04/2022 13:42
April 26 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS ENROLLS FIRST PATIENT IN PHASE 2B
STUDY
OF HALO-LIDO FOR THE PRESCRIPTION TREATMENT OF HEMORRHOIDS
* CITIUS PHARMACEUTICALS INC- RESULTS OF PHASE 2B STUDY OF
HALO-LIDO TRIAL ARE EXPECTED IN SECOND HALF OF 2023
Source text for Eikon: ID:nPn2rjGXra
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules